1.410 s

-0.040 (-2.76%)
Range 1.400 - 1.450   (3.57%)
Open 1.430
Previous Close 1.450
Buy Price 1.400
Buy Volume 29
Sell Price 1.420
Sell Volume 10
Volume 1,270,460
Value -
Remark s
Measurement Type Value
EPS (USD) -0.236
Trailing EPS (USD) -0.315
NAV (USD) 0.55
Cash In Hand (USD) 0.18
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 2.638
Price / Cash In Hand 8.065
Issued & Paid-up Shares 320,599,000
Treasury Shares -
Market Cap (M) 464.869
Par Value (USD) n.a.
Beta - 75 Days 0.176
R-Squared - 75 Days(%) 0.05
Beta - 500 Days 0.802
R-Squared - 500 Days(%) 11.1
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 29 Sep 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 04 Nov 2021
View All Events

About GERON CORP

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.

There are 6 followers

Investor
Followers
0
Followers
0
Followers
0
Followers
0
LCH
Followers
0
Followers
0